Ovid Therapeutics Inc (OVID) USD0.001

Sell:$0.27Buy:$0.28$0.03 (9.54%)

NASDAQ:0.32%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.27
Buy:$0.28
Change:$0.03 (9.54%)
Market closed | Prices delayed by at least 15 minutes
Sell:$0.27
Buy:$0.28
Change:$0.03 (9.54%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).

Key people

Jeremy Max Levin
Chairman of the Board, Chief Executive Officer
Margaret Alexander
President, Chief Operating Officer
Jeffrey Rona
Chief Business and Financial Officer
Bart Friedman
Lead Independent Director
Karen Bernstein
Independent Director
Barbara G. Duncan
Independent Director
Kevin Fitzgerald
Independent Director
Stelios B. Papadopoulos
Independent Director
Click to see more

Key facts

  • EPIC
    OVID
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6904691010
  • Market cap
    $20.68m
  • Employees
    23
  • Shares in issue
    71.11m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.